This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inside Last Week's Wall Street Rally & Best-Performing ETF Areas
by Sanghamitra Saha
Wall Street soared last week as strong jobs data and easing trade tensions sparked market optimism.
Best-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street soared last week as strong jobs data and easing trade tensions sparked market optimism. HIMS, BOIL, RGTX, NVOX, and MSFL were the top-performing leveraged ETFs last week.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
by Zacks Equity Research
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
by Shaun Pruitt
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $62.62 in the latest trading session, marking a +0.87% move from the prior day.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
by Zacks Equity Research
RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?
by Kinjel Shah
Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Pfizer Halts Obesity Pill Development Amid Safety Concerns
by Zacks Equity Research
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.